---
document_datetime: 2023-09-21 17:48:32
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/nespo-epar-procedural-steps-taken-authorisation_en.pdf
document_name: nespo-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5241189
conversion_datetime: 2025-12-25 11:09:44.312842
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Amgen  Europe  B.V.  submitted  on  17  December  1999  an  application  for  Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Nespo, in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the  Annex  to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Medicinal product no longer authorised Rapporteur: Prof. R. Bass Co-Rapporteur: Dr. D. Brasseur Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 21 January 2000. · The Rapporteur's first assessment report was circulated to all CPMP Members on 3 April 2000. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 4 April 2000. · The  CPMP  at  its  meeting  of  11-13  April  2000  decided  that  there  was  a  need  for  a  GMP inspection of the active  substance manufacturing  site. An  inspection  of three contract laboratories (Rockville, MD; Malvern, PA; Camden, New Jersey) was also requested. · During the meeting on 23-24 May 2000 the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the company on 25 May 2000. · The company submitted the responses to the CPMP consolidated list of questions on 12 October 2000. · The  company  submitted  on  22  November  2000  Certificates  of  suitability  from  the  European Pharmacopoeia for two of the suppliers of the Foetal bovine serum used during the manufacture of Nespo. · The Rapporteur circulated the joint response assessment report on the company's responses to the list of questions to all CPMP Members on 24 November 2000. · During the CPMP meeting on 12-14 December 2000, the CPMP issued a list of outstanding questions to be addressed by the applicant during an oral explanation. · The applicant submitted to the EMEA and the CPMP members on 8 January 2001 responses to the outstanding quality questions from the response assessment report. · The Rapporteur circulated an Amendment to the Response Assessment Report on Part II to all CPMP members on 10 January 2001.

- During the BWP meeting of 16-17 January 2001, all outstanding quality issues were discussed. The BWP prepared a Recommendation to the CPMP.
- The  applicant  submitted  to  the  EMEA  and  the  CPMP  members  on  10  and  16  January  2001 background documentation for the oral explanation.
- The Rapporteur and Co-Rapporteur circulated an Amendment to the Joint Assessment Report on 19 January 2001.

<div style=\"page-break-after: always\"></div>

- During the CPMP meeting of 23-25 January 2001, the outstanding issues were addressed by the applicant during an oral explanation before the CPMP.
- During the meeting on 27 February - 1 March 2001, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting Marketing Authorisations to Nespo on 1 March 2001.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 8 June 2001.

<!-- image -->